GlassScriptPhysician profile
Arun K Gupta
NPI 1295756054
$8,328.19
in general payments reported to CMS, 2019-2025
54 companies · $886 in 2025
The $886 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2020: $1,349 · 2021: $1,278 · 2022: $1,031 · 2023: $1,041 · 2024: $1,278 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,178 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.64 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,070.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $914.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $798.41 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $684.03 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $502.05 | 2019-2022 | |
| Abbvie INC. | $490.04 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.78 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $278.21 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $233.21 | 2023-2024 | Aptiom, Gemtesa |
| Otsuka America Pharmaceutical, INC. | $204.93 | 2020-2024 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $203.55 | 2019-2025 | Capvaxive |
| Astellas Pharma US INC | $199.36 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $192.59 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $172.73 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $171.84 | 2019-2024 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.